Sanofi shared a post on X:
“Our investigational BTK inhibitor for the potential treatment of wAIHA was granted Breakthrough Therapy Designation by US FDA
and Orphan Drug by MHLW of Japan in Japan, validating our commitment to helping address unmet needs for people living with rare diseases. Learn more.”